random trial carboplatin versu iproplatin untreat advanc ovarian cancer between august octob patient stage IC IV epitheli ovarian cancer carboplatin iproplatin week initi treatment stratif intern feder gynecolog obstetr figo stage size residu diseas surgeri respons cours patient laparoscopi laparotomi clinic complet respond assess diseas treatment proven complet respond patient partial PR minor respons MR cours origin drug dose carboplatin iproplatin patient stabl SD progress PD recurr diseas cyclophosphamid respons rate confid interv CI carboplatin CI iproplatin fifteen patient assess respons median surviv week CI week carboplatin patient week CI week iproplatin patient amount residu diseas initi laparotomi prognost factor surviv myelosuppress main toxic iproplatin studi carboplatin activ iproplatin treatment ovarian cancer toxic few respons drug resist alkyl agent 